According to this article, the top rated Endocrinologists in Milwaukee, WI are:
Dr. Diana L. Maas, MD – is an endocrinology, diabetes, and metabolism specialist
Dr. Elaine C. Drobny, MD – is board certified in internal medicine and endocrinology
Dr. Brent Jones, MD – is an Endocrinology Specialist has over 12 years of experience
Dr. Jenna Sarvaideo, DO – specializes in Endocrinology, Diabetes & Metabolism
Dr. Betiel F. Voss, MD – is a specialist in endocrinology with over 9 years of experience
Dr. Diana L. Maas, MD
Dr. Diana L. Maas, MD since early 1990, has worked in the field of endocrinology, diabetes, and metabolism. At the Medical College of Wisconsin and Affiliated Hospitals, she earned her medical training and finished her residency and fellowship. Dr. Maas is the Director of the Pituitary Clinic and an Associate Professor of Medicine. She collaborates with neurosurgeons to treat patients with pituitary tumors as a team.
Products/Services:
Endocrinologists
LOCATION:
Address: Froedtert Hospital, 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: (414) 805-3666 Website: www.froedtert.com
REVIEWS:
“My absolute favorite MD. Dr. Maas gets to know her patients and is very thorough. Dr. Maas gave me my life back and I will always love her for that. If you want a great Endocrinologist, she’s your best bet.” – Veronica M.
Dr. Elaine C. Drobny, MD
Dr. Elaine C. Drobny, MD is board certified in endocrinology, internal medicine, diabetes, and metabolism. Dr. Drobny graduated from the University of Arizona School of Medicine in 1977 and went on to Northwestern Memorial Hospital in Chicago for her internship and residency in internal medicine. At Northwestern University Hospitals, she completed an endocrinology fellowship. Professional Research Consultants, Inc., a leader in health care research, named Dr. Drobny a “Top Performer” in their 2019 awards, which are based on overall doctor ratings from patient surveys.
“I appreciated the thorough review of all my concerns about my health as it relates to my Osteoporosis and necessary treatment. Also, Dr. Drobny, Nurse & staff are very courteous, pleasant & punctual, very little wait time.” – Elizabeth G.
Dr. Brent Jones, MD
Dr. Brent Jones, MD is a Milwaukee, Wisconsin-based endocrinology, diabetes, and metabolism specialist with over 12 years of experience. Dr. Jones has greater experience than other physicians in his area with osteoporosis and screening, thyroid disorders, and diabetes and glucose monitoring. In 2009, he received his medical degree from Dartmouth College. Ascension Columbia St. Mary’s Hospital Ozaukee and Ascension Columbia Saint Mary’s Hospital Milwaukee are both affiliated with him. He is now taking new patients and has stated that telemedicine appointments are acceptable.
“Having Dr. Jones as my endocrinologist has made my life with type 1 diabetes the most enjoyable, thankful and grateful since I was diagnosed when I was a young kid. His personality is one to behold. He treats his patients with the utmost respect, and his friendliness is like him being your best friend. I appreciate that very much. I have to thank him for being the one and only doctor who I would choose to help me with my diabetes.” – Patrick Z.
Dr. Jenna Sarvaideo, DO
Dr. Jenna Sarvaideo, DO practices Endocrinology, Diabetes, and Metabolism in Evanston, as well as four other locations. Northshore University Health System Evanston Hospital, Froedtert & The Medical College Of Wisconsin Community Memorial Hospital Campus, and Froedtert Lutheran Memorial Hospital are all linked with Dr. Sarvaideo.
Products/Services:
Endocrinologists
LOCATION:
Address: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: (414) 805-3666 Website: www.froedtert.com
REVIEWS:
“Dr. Sarvaideo is incredibly kind and caring and will do whatever she can to help. I’ve seen her for almost 3 years and I recommend her to anyone who is LGBTQ+ and looking to start their journey.” – Niki P.
Dr. Betiel F. Voss MD
Dr. Betiel F. Voss MD is a specialist in endocrinology in Milwaukee, Wisconsin. In 2012, she received her bachelor’s degree with honors from the University of Texas Medical Branch at Galveston. Dr. Betiel F Voss is affiliated with many hospitals, including Aurora West Allis Medical Center, and Aurora St Lukes Medical Center and collaborates with many other doctors and specialists in the medical group Aurora Medical Group, Inc. Dr. Betiel F Voss has more than 9 years of diverse experience, especially in endocrinology.
“It’s rare that I go out of my way to review a medical practitioner, but Dr. Betiel Voss deserves special recognition. She’s a caring doctor with a wonderful bedside manner. She offers proactive patient education regarding findings as well. If you’re looking for an endocrinologist, she’s worth the wait.” – Stephanie S.
Endocrinology is a medical specialty that focuses on the diagnosis and treatment of diseases related to hormones. Endocrinologists are experts in managing and treating diseases related to the endocrine system, which includes the thyroid, pituitary, adrenal glands, and pancreas. Endocrinologists are trained to diagnose and treat conditions such as diabetes, thyroid disorders, pituitary disorders, and other conditions related to hormones. Endocrinologists also specialize in reproductive health and fertility issues, including PCOS.
Endocrinology is a complex field that requires a deep understanding of the endocrine system and its role in regulating the body’s hormones. Endocrinologists must be able to interpret laboratory tests and understand the underlying causes of endocrine disorders. They must also be able to develop individualized treatment plans to address the specific needs of each patient.
Diagnosing PCOS and Diabetes
Endocrinologists are experts in diagnosing and managing PCOS and diabetes. PCOS is a hormonal disorder that affects the ovaries, and it is characterized by irregular menstrual cycles, excess facial and body hair, and infertility. To diagnose PCOS, an endocrinologist will perform a physical exam and order laboratory tests to measure hormone levels. The endocrinologist will also ask the patient about her symptoms and family history to determine if PCOS is the cause.
Diabetes is a chronic condition that affects the body’s ability to process sugar. To diagnose diabetes, an endocrinologist will perform a physical exam and order laboratory tests to measure blood sugar levels. The endocrinologist may also order imaging tests to check for signs of diabetes-related complications.
Treating PCOS and Diabetes
Once the endocrinologist has diagnosed PCOS or diabetes, they will develop an individualized treatment plan to address the patient’s specific needs. For PCOS, the endocrinologist may recommend lifestyle changes such as weight loss, exercise, and dietary changes to help manage symptoms. The endocrinologist may also prescribe medications to regulate hormone levels and improve fertility.
For diabetes, the endocrinologist may recommend lifestyle changes such as weight loss, exercise, and dietary changes to help manage blood sugar levels. The endocrinologist may also prescribe medications to help regulate blood sugar levels. In addition, the endocrinologist may recommend regular check-ups to monitor the patient’s progress and to adjust the treatment plan if needed.
Conclusion
Endocrinology plays an important role in managing PCOS and diabetes. Endocrinologists are experts in diagnosing and treating these conditions, and they are trained to develop individualized treatment plans that address the specific needs of each patient. By working with an endocrinologist, patients can get the help they need to manage their PCOS or diabetes and achieve their health goals.
Endocrinology is a complex field that requires a deep understanding of the endocrine system and its role in regulating the body’s hormones. An endocrinologist can help patients with PCOS and diabetes manage their conditions and achieve their health goals. By working with an endocrinologist, patients can get the help they need to manage their PCOS or diabetes and achieve their health goals.
We are delighted to welcome Dr. Leena Shahla to the Pituitary Podcast. She is the director of The Duke Pituitary Program. Today she joins PWN co-founder and medical director of the California Center for Pituitary Disorders at UCSF, Dr. Lewis Blevins, for an in-depth discussion about pseudo-Cushing’s syndrome.
In the Duke Health web portal, Dr. Shahla says endocrinology captured her heart because it combines medical science with unique challenges. “My passion for solving puzzles drives my deep interest in pituitary disease, the most complex area of endocrinology.” You can read more about Dr. Shahla, her practice and background here.
This is a fascinating discussion about a complex, often misunderstood condition by two of the leading experts in the field you won’t want to miss it. Pseudo–Cushing’s syndrome or non-neoplastic hypercortisolism is a medical condition in which people with this disorder display the signs, symptoms, and abnormal cortisol levels.  Common causes can include  pregnancy, alcohol use disorder, morbid obesity, polycystic ovarian syndrome, end-stage renal disease, severe major depressive disorder, and poorly controlled diabetes.
Diagnosed with a rare disease that only affects between two and ten people per million, Marie Conley used emails to communicate with family, friends, and co-workers to keep them apprised of the diagnosis and prognosis of Cushing’s disease and the many complications she experienced on this journey. Her ironic humor and raw, emotional approach helps bring hope to those touched by this rare and unrelenting disease.
In her mid-thirties, Conley, who strived to keep herself healthy while maintaining the delicate balance of raising a young child, keeping a home, and a demanding career, began to experience a variety of unexplained maladies inconsistent with her life style.Because of the elusive nature of Cushing’s disease, the treatment is a long and complicated process of trial and error.
At this time, there is no cure, largely due to the fact that Cushing’s disease is considered an “orphan disease.” As is her nature, she has decided to “adopt” this “orphan” and is doing everything she can to bring awareness to this disease.Conley’s tenacious spirit and determination would not allow this insidious disease to triumph over her life. Armed with her laptop as the only weapon available in the sterility of the recovery room, the author attacks the keyboard with a vengeance to let friends and family know that in this battle, there is no surrender.
Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue.
A 35-year-old woman is seen in the outpatient clinic for evaluation of an incidental pituitary macroadenoma. Her medical history is significant for hypertension, diabetes, hyperlipidemia, polycystic ovary syndrome, and obesity. She initially presented to the emergency department (ED) a week ago after an episode of right visual field changes that she described as waviness in her right eye and right hemibody sensory changes without motor deficits. While in the ED, she underwent a full workup for possible stroke, which was negative. Magnetic resonance imaging (MRI) of her brain without contrast revealed a 12-mm pituitary lesion; a repeat MRI with contrast was then ordered (Figure). No serum hormonal panel was available for review from ED records.
Figure. Magnetic resonance imaging of the case patient. Left image: sagittal view. Right image: coronal view with contrast. Credit: Melissa Wasilenko, MSN, RN
Upon further questioning of her medical history during the clinic visit, the patient notes that a few years ago she was attempting to become pregnant and was evaluated by her gynecologist for amenorrhea. At that time, she reportedly completed an endocrine laboratory workup that showed a slightly elevated prolactin level between 30 and 40 ng/mL (normal level in nonpregnant women, <30 ng/mL). Per the patient, the minimal elevation was not enough to concern the gynecologist and no MRI was ordered at that time. Her gynecologist recommended that she lose weight. Her menses returned to normal with weight loss. With a history of disrupted menstrual cycles, infertility, and patient reported elevated prolactin level, there is high suspicion for endocrine disruption. A complete pituitary panel is ordered again to examine the current hormone function considering the recent MRI findings. This revealed a prolactin of 33.7 ng/ml, and all other hormonal levels were within normal limits.
Because the patient reports multiple episodes of visual disturbances and the size of the pituitary adenoma on MRI, a neuro-ophthalmology referral is initiated for visual field testing and to determine if the pituitary macroadenoma is causing mass effect and compressing the optic nerve. The neuro-ophthalmologist found she had no visual field defect from her adenoma on visual field testing and believed that her visual disturbances were probably migraine in nature.
Discussion
Pituitary gland tumors are usually found incidentally on imaging studies obtained for other reasons or in workup of patients with abnormal endocrine hormone levels (both decreased and increased levels) or with symptoms of mass effect from the lesions.1Â These tumors are typically benign in nature; cases with malignancy are extremely rare.1Â The exact pathophysiology of pituitary adenomas remains unknown but is thought to be linked to heredity, hormonal influences, and genetic mutations.1
Pituitary tumors are commonly found in adults between the ages of 35 and 60 years of age.2,3 The estimated prevalence of pituitary adenomas varies widely by study and findings are typically based on autopsy and radiology data. Surveillance, Epidemiology, and End Results (SEER) Program data from 2004 to 2018 show an incidence rate of pituitary adenomas and pituitary incidentalomas of 4.28 ± 0.04 and 1.53 ± 0.02 per 100,000 population.4 Pituitary tumors have been found in 14.4% of unselected autopsy cases and 22.5% of radiology tests.1
The SEER data suggest that incidence rates are similar among women and men but are higher among women in early life and higher among males in later life.5Â Rates of prolactinomas (prolactin-secreting tumors) and corticotropinomas (adrenocorticotropic hormone-secreting tumors; Cushing disease) are higher in women than men.6
Earlier SEER data showed a significantly higher incidence of pituitary adenomas in Black individuals compared with other racial/ethnic groups; several factors may account for this discrepancy such as the higher stroke rate in this population, which leads to a greater likelihood for brain imaging that detects incident pituitary tumors.5
Incidental findings of pituitary adenoma may be found during workup related to hormonal dysfunction (amenorrhea, galactorrhea, fertility disorders, sexual dysfunction), noticeable vision change, new-onset headaches, or imaging performed for other diagnostic purposes.7
Pituitary Types
Pituitary tumor types are differentiated by location, size, and functional status. Pituitary tumors commonly arise from the anterior portion of the gland (adenohypophysis) and rarely from the posterior portion (neurohypophysis).2Â Both adenohypophyseal and neurohypophyseal tumors are commonly benign and slow-growing.1Â Malignant pituitary tumors account for less than 1% of pituitary lesions and are usually metastases from breast and lung cancers.3Â Adenohypophyseal carcinoma is rare, with less than 140 reported cases.2
Pituitary tumors are categorized by the size1,2:
Microadenomas (<10 mm)
Macroadenomas (>10 mm to 40 mm)
Giant adenomas (>40 mm)
Pituitary adenomas are further classified as functioning (hormone-secreting) or nonfunctioning (nonsecreting).1,6Â If the adenoma is functioning, hormone levels will be found in excess. If the levels are within normal limits, a nonfunctioning pituitary adenoma is suspected.
Functioning Tumors
Approximately 65% of all pituitary adenomas are functioning tumors.2Â Functioning pituitary adenomas present in various ways depending on which hormone is involved and the level of hormone secretion. Prolactinomas are the most common type of functioning adenomas followed by growth hormone-secreting and adrenocorticotropic hormone-secreting pituitary tumors. Adenomas secreting thyrotropin and follicle-stimulating hormone are less commonly found.2Â Clinical features of functional pituitary adenomas are outlined in Table 1.2.8
Table 1. Clinical Features and Laboratory Findings of Functioning Pituitary Adenomas
Nonfunctioning Tumors
Approximately 20% to 30% of pituitary adenomas are nonfunctional.3Â These tumors may go undiagnosed for years until the mass of the tumor starts to effect surrounding structures and causing secondary symptoms such as compression of the optic chiasm causing vision impairments.
Nonfunctioning pituitary adenomas and prolactinomas (functioning) are the 2 most common types of pituitary adenomas.2,3Â The consulting clinician must understand the difference in pathology of these 2 types of lesions, what diagnostic test to order, how to interpret the test results, and which specialty to refer the patient to best on the initial workup findings.
Initial Workup
Proper baseline workup should be initiated before referring patients with incidental pituitary adenoma to a specialist. The initial workup includes imaging, blood work to determine if the pituitary adenoma is causing hormonal dysfunction, and neuro-ophthalmology referral for visual field testing to determine if the optic nerve/chiasm is impacted.
Imaging
The most accurate diagnostic modality of pituitary gland pathology is MRI with and without contrast. The MRI should focus on the hypothalamic-pituitary area and include contrasted imaging to evaluate the soft tissue within the intracranial structure.9Â The coronal and sagittal views are the best to display the pituitary gland width and height and identify abnormalities.9Â The MRI provides a detailed evaluation of the pituitary gland related to adjacent structures within the skull, which helps to detect microalterations of the pituitary gland.10Â If a pituitary adenoma is an incidental finding on another imaging modality (such as a computed tomography scan or MRI without contrast), an MRI with and without contrast that focuses on the pituitary gland should be obtained.
Pituitary Laboratory Panel
A complete pituitary panel workup should be obtained including prolactin, thyrotropin, free thyroxine, cortisol (fasting), adrenocorticotropic hormone, insulinlike growth factor 1, growth hormone, follicle-stimulating hormone, luteinizing hormone, estradiol in women, and total testosterone in males.1Â Tests should be completed in the morning while fasting for the most accurate results. For instance, normally cortisol levels drop during fasting unless there is abnormality. Table 2 below shows normal laboratory ranges for a complete pituitary panel.
Serum prolactin levels can slightly increase in response to changes in sleep, meals, and exercise; emotional distress; psychiatric medications; and oral estrogens. If the initial prolactin level is borderline high (21-40 ng/mL), the test should be repeated. Normal levels are higher in women than in men. Microadenomas may cause slight elevations in prolactin level (ie, <200 ng/mL), while macroadenomas are likely to cause greater elevations (ie, >200 ng/mL).1Â Patients with giant prolactinomas typically present with prolactin levels ranging from 1000 ng/mL to 100,000 ng/mL.11
Perimetry
Pituitary adenomas may cause ophthalmologic manifestations ranging from impaired visual field to diplopia because of upward displacement of the optic chiasm. The optic chiasm is located above the pituitary gland and a pituitary tumor that grows superiorly can cause compression in this area.12Â Optic chiasm compression from a pituitary adenoma commonly causes bitemporal hemianopsia.2Â If the tumor volume is promptly reduced by surgical resection or medication (in the case of prolactinomas), initial vision changes due to compression may be reversible.12
Baseline and routine follow-up perimetry are important in patients with pituitary adenoma, as symptoms of optic chiasm compression may go unnoticed by patients as visual field deficits often develop gradually. Also, post-treatment perimetry assessments can be used to compare the initial testing to evaluate reversible visual field deficits. It is recommended that patients with pituitary adenomas (both function and nonfunctiong) receive neuro-ophthalmologic evaluations twice a year to ensure no visual changes have occurred.12
Referral to a Specialist
Management of pituitary adenomas requires a multidisciplinary team of specialists including endocrinologists, neurosurgeons, and neuro-ophthalmologists. The type of adenoma governs which specialist patients with incidental adenoma should see first.
Patients with functioning pituitary adenomas should be referred to an endocrinologist before a neurosurgeon. The most prevalent functioning adenomas, prolactinoma, are initially treated with dopamine agonist medications.1,6Â A patient with prolactinoma would only need to see a neurosurgeon if they have a macroadenoma that is not responsive or only partially responsive to dopamine agonists therapy or is causing vision deficits related to compression of the optic chiasm.2
Patients with nonfunctioning pituitary adenomas should first be referred to a neurosurgeon to discuss surgical options versus observation. The recommended treatment for patients with nonfunctioning adenomas and clinical features of mass effect (ie, visual deficits) is surgery.1,6Â If the patient is asymptomatic with no signs of visual field deficits, the neurosurgery team may recommend continued surveillance with serial imaging and serial perimetry screenings.12
The patient in the case was found to have a nonfunctioning pituitary adenoma (prolactin was 33.7 ng/mL). Neuro-ophthalmology did not find any visual field defect upon initial assessment; the patient decided to continue observation with serial imaging (MRI) and serial neuro-ophthalmology assessments. Serial imaging with MRI brain revealed slow but real progression of the pituitary macroadenoma (12 mm initially; 13 mm 6 months later; and 14 mm 1 year from initial MRI findings). Although the patient still did not have any visual field defects per the neuro-ophthalmology reassessments, the documented growth on MRI over a short period of time was enough to make the patient more amendable to surgical resection. The patient underwent trans-sphenoidal resection of the pituitary lesion approximately 16 months after discovery of the tumor.
Conclusion
A thorough workup including laboratory testing, imaging, and vision field testing is the foundation of an effective referral process for pituitary adenomas and guides which specialist is consulted first. If patients are referred before initial workup is completed, delays in care, unnecessary specialty visits, and increased overall health care costs may occur.
Melissa Wasilenko, MSN, RN, is a registered nurse at Lyerly Neurosurgery in Jacksonville, Florida. She is currently pursuing a doctorate in nursing practice with a focus in family medicine at the University of North Florida in Jacksonville.
Here’s your chance to make your voice heard on your health Issues.
We have hundreds of studies open for patients and caregivers! Some of the studies we are working to fill immediately are listed below.
1. If you are already a member of Rare Patient Voice and want to be considered for a study listed below, please contact study.inquiries@rarepatientvoice.com
2. If you are NOT a member, please click here to complete the sign-up process and include all medical conditions to be considered for one or more of the studies below and any other relevant studies.
Please feel free to share this page with friends or family who might be interested!
United States
Congenital Adrenal Hyperplasia (CAH) patients United States
This is a 5-minute survey for a medical history platform, compensation is a $25 gift card
Crohn’s Disease, Diabetes, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis caregivers of children in Philadelphia, PA United States
75-minute in-person interviews, compensation is $225
Crohn’s Disease Male Non-Caucasian Patients United States
90-minute web-assisted phone interview, compensation is $175 ($150 for the interview and $25 for confirmation of diagnosis)
Crohn’s Disease, Ulcerative Colitis patients United States
15-minute online survey, compensation is $30
Growth Hormone Deficiency (GHD), Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS), Small for Gestational Age (SGA), Turner Syndrome patients or caregivers in Boston, Charlotte, Raleigh, and Orlando United States
3-hour in-person interview
Migraine patients United States
Online surveys over a 6-10 week period, compensation is $325 to $585
Osteoporosis/Osteopenia patients who currently use or have used Forteo United States
60-minute in-person interview, compensation is $180
United Kingdom
Neuroendocrine Cancer (NET) patients United Kingdom
45-60 minute web-assisted phone interview, compensation is 50 GBP
Frequently Asked Questions
Why sign up with Rare Patient Voice?
Who knows better than you about your journey and experiences? We connect you with researchers who are developing products and services which can help you and others with your condition. These researchers need patient input so that they develop products and services that have a meaningful impact on patients’ lives.How will I be paid?
You will earn $120 per hour for participating in studies. We pay by check to ensure patients/family caregivers can use their compensation in any way they wish, and now provide the option for patients/family caregivers to sign up for electronic payments.
About Rare Patient Voice
Rare Patient Voice connects patients and caregivers with researchers who are developing products and services to help you and others with your condition. RPV has paid patients and family caregivers over $13 million dollars since 2013 for participating in research studies.
COVID-19 Vaccine booster shots are available for the following Pfizer-BioNTech vaccine recipients who completed their initial series at least 6 months ago and are:
Dr. Friedman is getting a lot of emails on booster shots versus third shots. Third shots are for immuno-compromised patients that the FDA is recommending for a small group of patients The FDA also has the intention to soon make booster doses widely available to all healthy individuals. I am writing to clarify the difference between booster shots and third doses.
Third Doses for Immuno-Compromised Patients
The purpose of a third dose of mRNA vaccine is to give immuno-compromised patients the same level of protection that two doses provide someone who has a normal immune system. It is recommended that the following people get a third dose
Been receiving cancer treatment for tumors or cancers of the blood
Received an organ transplant and are taking medicine to suppress the immune system
Received a stem cell transplant within the last two years or are taking medicine to suppress the immune system
Been diagnosed with moderate or severe immunodeficiency conditions (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
An advanced or untreated HIV infection
Been under active treatment with high-dose corticosteroids (> 20 mg of prednisone or 100 mg of hydrocortisone) or other drugs that may suppress immune response
Dr. Friedman thinks it is unlikely that any of his patients have these conditions. Patients with Cushing’s syndrome, Addison’s, diabetes or thyroid disorders do not qualify.
In contrast, a Booster Dose is for Patients With Healthy Immune Systems
A booster dose—which is different from a third dose for immuno-compromised patients—is for healthy patients and is meant to enhance immunity and may protect against new variants of the virus.The Biden administration has announced that it intends to make booster doses available for people with healthy immune systems in September 2021, after they are authorized or approved by the FDA. This has not happened yet, but when it happens, Dr. Friedman would encourage his patients to get it.
Dr. Friedman is expecting a booster shot against the Delta variant to be released in the fall of 2021 and would recommend that for his patients.
Dr. Friedman wishes everyone to stay healthy.
Murfreesboro Medical Clinic & SurgiCenter is committed to meeting the needs of Rutherford County’s growing community. In addition to adding two new locations in 2019, MMC will be adding five new doctors to its team of physicians.
The physicians joining MMC this fall are: Christopher Albergo, M.D. (Endocrinology), Lauren Blackwell, D.O. (Pediatrics), C. Brad Bledsoe, M.D. (Dermatology), Britni Caplin, M.D. (ENT), and Brittany Cook, M.D. (Ophthalmology).
“With a national shortage of physicians, it is becoming more and more challenging to find quality physicians to meet the growing healthcare needs of our community,” noted Joey Peay, MMC’s Chief Executive Officer. “For MMC to find five quality physicians to join us in 2019 in addition to the nine that began practicing at MMC in 2018 is truly remarkable! Each of them will be a valuable member of our medical team and a wonderful member of the Murfreesboro community.”
Christopher Albergo, M.D. is a board-certified Endocrinologist skilled in general endocrinology, including Hypothyroid, Parathyroid, Thyroid Cancer, Graves’ Disease, Pituitary disorders, Adrenal disorders, Hypogonadism , PCOS, Obesity, Diabetes and Osteoporosis.
